Document is current
Any future updates will be listed below
-
Authors
Kimble, Erik L https://orcid.org/0000-0002-1885-1773
Wright, Jocelyn H https://orcid.org/0000-0003-1548-0847
Torkelson, Aiko
Kirchmeier, Delaney R
Braathen, Kristina https://orcid.org/0009-0003-5362-1556
Ruff, Raymond O
Shimp, Kristen R
Seaton, Brandon W
Gauthier, Jordan https://orcid.org/0000-0002-5769-8409
Kolokythas, Orpheus
Boiani, Norman E
Jellyman, David
Yeung, Cecilia CS
Tam, Eric
Price, Jason P
Hirayama, Alexandre https://orcid.org/0000-0001-7980-3882
Turtle, Cameron J
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01865617 at ClinicalTrials.govDocuments that mention this clinical trial
Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufacture
https://doi.org/10.1136/jitc-2023-008723
Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs
https://doi.org/10.1136/jitc-2025-013123
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
https://doi.org/10.1136/jitc-2020-001511
Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.
https://doi.org/10.1200/jco.2023.41.16_suppl.7511
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (U54-DK106829)
Fred Hutchinson Cancer Center Immunotherapy Integrated Research Center (20016117)
Swim Across America (N/A)
National Health and Medical Research Council (2033771)
American Society for Cell and Gene Therapy (N/A)
Washington Research Foundation (N/A)
Anthony Rothe Memorial Trust (N/A)
National Cancer Institute (5K12CA076930-25)
University of Washington Department of Medicine (N/A)
CLEARbridge Foundation (N/A)
- License Information
